DE69331524D1 - Verfahren zum spezifischen schneiden von rna-strängen - Google Patents

Verfahren zum spezifischen schneiden von rna-strängen

Info

Publication number
DE69331524D1
DE69331524D1 DE69331524T DE69331524T DE69331524D1 DE 69331524 D1 DE69331524 D1 DE 69331524D1 DE 69331524 T DE69331524 T DE 69331524T DE 69331524 T DE69331524 T DE 69331524T DE 69331524 D1 DE69331524 D1 DE 69331524D1
Authority
DE
Germany
Prior art keywords
rna strands
specific cutting
activator
cutting
antisense oligonucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69331524T
Other languages
English (en)
Other versions
DE69331524T2 (de
Inventor
Paul Torrence
Robert Silverman
Ratan Maitra
Krystyna Lesiak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
US Government
Original Assignee
CLEVELAND CLINIC RESEARCH INSTITUTE CLEVELAND
US Department of Health and Human Services
Cleveland Clinic Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CLEVELAND CLINIC RESEARCH INSTITUTE CLEVELAND, US Department of Health and Human Services, Cleveland Clinic Research Institute filed Critical CLEVELAND CLINIC RESEARCH INSTITUTE CLEVELAND
Application granted granted Critical
Publication of DE69331524D1 publication Critical patent/DE69331524D1/de
Publication of DE69331524T2 publication Critical patent/DE69331524T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69331524T 1992-10-21 1993-10-20 Verfahren zum spezifischen schneiden von rna-strängen Expired - Fee Related DE69331524T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96566692A 1992-10-21 1992-10-21
US08/123,449 US5583032A (en) 1992-10-21 1993-09-17 Method of cleaving specific strands of RNA
PCT/US1993/010103 WO1994009129A2 (en) 1992-10-21 1993-10-20 Method of cleaving specific strands of rna

Publications (2)

Publication Number Publication Date
DE69331524D1 true DE69331524D1 (de) 2002-03-14
DE69331524T2 DE69331524T2 (de) 2002-09-19

Family

ID=26821570

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69331524T Expired - Fee Related DE69331524T2 (de) 1992-10-21 1993-10-20 Verfahren zum spezifischen schneiden von rna-strängen

Country Status (9)

Country Link
US (3) US5583032A (de)
EP (1) EP0666910B1 (de)
JP (1) JP3529135B2 (de)
AT (1) ATE212664T1 (de)
AU (1) AU669250B2 (de)
CA (1) CA2147282A1 (de)
DE (1) DE69331524T2 (de)
HK (1) HK1013103A1 (de)
WO (1) WO1994009129A2 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202225B1 (en) * 1993-10-15 2007-04-10 Emanuele R Martin Therapeutic delivery compositions and methods of use thereof
US20020123476A1 (en) * 1991-03-19 2002-09-05 Emanuele R. Martin Therapeutic delivery compositions and methods of use thereof
US20040127446A1 (en) * 1992-05-14 2004-07-01 Lawrence Blatt Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
KR19990067080A (ko) 1995-10-27 1999-08-16 엘리엇 알. 램버그 특정 뉴클레오티드 서열의 검출방법 및 조성물
US5998203A (en) * 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
US5998602A (en) * 1996-02-15 1999-12-07 The Cleveland Clinic Fouindation And Government RNase L activators and antisense oligonucleotides effective to treat RSV infections
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20040171028A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
DE19631918A1 (de) * 1996-08-07 1998-02-12 Deutsches Krebsforsch Steigerung der Wirkung von Anti-Sinn-RNA in Zellen
US6468983B2 (en) * 1997-04-21 2002-10-22 The Cleveland Clinic Foundation RNase L activators and antisense oligonucleotides effective to treat telomerase-expressing malignancies
US20030165888A1 (en) * 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
GB2335034B (en) * 1998-03-03 2003-08-20 Brax Genomics Ltd Screening for functional antisense agents
ES2358175T3 (es) * 1998-08-18 2011-05-06 Dermtech International Procedimiento para la detección de factores biológicos en la epidermis.
WO2000014219A2 (en) * 1998-09-04 2000-03-16 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Peptide nucleic acid-oligoadenylate chimeric molecules
WO2000052210A2 (en) * 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
CA2365984A1 (en) * 1999-04-08 2000-10-19 Oasis Biosciences, Inc. Antisense oligonucleotides comprising universal and/or degenerate bases
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
US8017742B2 (en) * 1999-11-10 2011-09-13 Japan Science And Technology Agency Gene carrier
US6806361B1 (en) * 2000-03-17 2004-10-19 Affymetrix, Inc. Methods of enhancing functional performance of nucleic acid arrays
US7297480B2 (en) * 2001-06-28 2007-11-20 Dermtech International Method for detection of melanoma
DE10133858A1 (de) * 2001-07-12 2003-02-06 Aventis Pharma Gmbh Synthetische doppelsträngige Oligonucleotide zur gezielten Hemmung der Genexpression
US20030171315A1 (en) * 2001-07-18 2003-09-11 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for therapeutic purposes
WO2004044132A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
EP1675454A4 (de) * 2003-08-19 2007-03-21 22Nd Century Ltd Llc Tabakprodukte mit verminderter exposition
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8470315B2 (en) 2004-04-13 2013-06-25 Quintessence Biosciences, Inc. Non-natural ribonuclease conjugates as cytotoxic agents
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
WO2006119466A2 (en) * 2005-05-04 2006-11-09 Immunotrex Corporation Methods for microorganism detection and identification
AU2006247739A1 (en) 2005-05-11 2006-11-23 Vector Tobacco Inc. Reduced risk tobacco products and methods of making same
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
EP2049151A4 (de) 2006-07-17 2010-03-24 Quintessence Biosciences Inc Verfahren und zusammensetzungen zur behandlung von krebs
US9102948B2 (en) 2006-11-17 2015-08-11 22Nd Century Limited, Llc Regulating alkaloids
WO2008131348A2 (en) * 2007-04-20 2008-10-30 Immunotrex Corporation Compositions and methods for treatment of uncontrolled cell growth
WO2008137772A1 (en) * 2007-05-04 2008-11-13 Dermtech International Diagnosis of melanoma by nucleic acid analysis
WO2009048909A1 (en) * 2007-10-08 2009-04-16 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapies
EP2242854A4 (de) * 2008-01-15 2012-08-15 Quark Pharmaceuticals Inc Sirna-verbindungen und verfahren zur verwendung davon
EP2682403B1 (de) 2008-05-08 2016-04-20 Monsanto do Brasil LTDA Gen und Verfahren zur Erhöhung der Krankheitsresistenz bei Pflanzen
CN102089444A (zh) 2008-05-14 2011-06-08 德玛泰克国际公司 利用核酸分析方法来诊断黑素瘤和太阳能雀斑
CA2734521A1 (en) * 2008-08-28 2010-03-04 Dermtech International Determining age ranges of skin samples
CN102227443B (zh) 2008-10-01 2014-05-14 昆特森斯生物科学公司 治疗性核糖核酸酶
US11976332B2 (en) 2018-02-14 2024-05-07 Dermtech, Inc. Gene classifiers and uses thereof in non-melanoma skin cancers
JP2021521831A (ja) * 2018-04-24 2021-08-30 ザ スクリプス リサーチ インスティテュート Ｒｎａへのヌクレアーゼの小分子による標的指向動員
AU2020247911A1 (en) 2019-03-26 2021-11-11 Dermtech, Inc. Novel gene classifiers and uses thereof in skin cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2567892B1 (fr) * 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons

Also Published As

Publication number Publication date
AU669250B2 (en) 1996-05-30
WO1994009129A2 (en) 1994-04-28
US5583032A (en) 1996-12-10
DE69331524T2 (de) 2002-09-19
US5677289A (en) 1997-10-14
EP0666910A1 (de) 1995-08-16
ATE212664T1 (de) 2002-02-15
WO1994009129A3 (en) 1994-05-26
HK1013103A1 (en) 1999-08-13
AU5585894A (en) 1994-05-09
US6271369B1 (en) 2001-08-07
JPH08502408A (ja) 1996-03-19
EP0666910B1 (de) 2002-01-30
JP3529135B2 (ja) 2004-05-24
CA2147282A1 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
DE69331524D1 (de) Verfahren zum spezifischen schneiden von rna-strängen
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
ATE151467T1 (de) Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
DK0698092T3 (da) Antisenseoligonukleotider, der bekæmper uregelmæssig splejsning,og fremgangsmåder til anvendelse deraf
DE69720473D1 (de) Verfahren zur reinigung von nukleinsäuren
JPH03123485A (ja) 特異的ｒｎａ配列を切断するｒｎａ触媒
DE69840748D1 (de) Verfahren zur zubereitung von antisense oligonukleotiden
HU9303023D0 (en) Peptide nucleicadis and method for producing them
DE69818304D1 (de) Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
FI951612A (fi) Menetelmiä synteettisten oligonukleotidien sekvensoimiseksi, jotka sisältävät nukleotidien välisiä ei-fosfodiesterisidoksia
DE69736598D1 (de) Ribonukleaseresistente rna präparation und seine verwendung
PT84207B (pt) Processo para a expressao de genes em plantas, fragmentos de adn, plasmideos e microrganismos transformados
ES2110604T3 (es) Metodo de secuenciacion de adn.
ATE317432T1 (de) Hiv-spezifische oligonukleotide und verfahren zu deren verwendung
ATE353973T1 (de) Die verwendung der 3'-wesentlichen bearbeitungswirksamkeit von dns-polymerase
ATE174065T1 (de) Simultane sequenzierung von nukleinsäuren
DE69936532D1 (de) Verfahren zum quantitativen nachweis von nukleinsäuren
DE69636835D1 (de) Verfahren zur verwendung der nukleotid-integrase zur spaltung von dna und zum einbau von nukleinsäuren
ATE419341T1 (de) Verfahren zur reduzierung der rna-konzentration in einer mischung biologischen materials unter verwendung von diatomeen-erde
BG101620A (en) Dna purification by the formation of a triple spiral with immobilized oligonucleotide
ATE366808T1 (de) Chimäre oligonukleotide und deren verwendungen in der identifizierung von antisense-bindungsstellen
DE59608651D1 (de) Verfahren zur sequenzierung durch oligomerhybridisierung
Yurchenko et al. Cleavage of Leishmania Mini-exon Sequence by Oligonucleotides Conjugated to a Dimidazole Construction
DK0625194T3 (da) Forøgelse af ribozym-katalytisk aktivitet med et tilstødende facilitator oligonukleotid
BR9305489A (pt) Plantas resistentes contra vírus plural e processo para produzir as mesmas

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS

Owner name: THE CLEVELAND CLINIC FOUNDATION, CLEVELAND, OHIO,

8339 Ceased/non-payment of the annual fee